未登录

J

John J. LiPuma

University of Michigan Medical School

H指数:75

被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating the association of antibiotic spectrum and treatment responses of cystic fibrosis pulmonary exacerbations

Journal of Cystic Fibrosis

IF6

2025-12-170

PRE

Intra-individual diversity of bacteriophage susceptibility in Burkholderia cultured from cystic fibrosis sputum

从囊性纤维化患者痰液中培养的Burkholderia中噬菌体易感性的个体内多样性

Journal of Cystic Fibrosis

IF6

2025-05-310

PRE

Evaluation of antimicrobial susceptibility testing methods for Burkholderia cepacia complex isolates from people with and without cystic fibrosis

JOURNAL OF CLINICAL MICROBIOLOGY

IF5.4

2025-02-190

OAAI

Daily variability of Pseudomonas aeruginosa density in cystic fibrosis sputum

铜绿假单胞菌在囊性纤维化痰液中的日间密度变化

JOURNAL OF CYSTIC FIBROSIS

IF6

2024-12-011

PRE

Frameshift Mutations in Genes Encoding PBP3 and PBP4 Trigger an Unusual, Extreme β-Lactam Resistance Phenotype in Burkholderia multivorans

ACS INFECTIOUS DISEASES

IF3.8

2024-10-230

PRE

Source-to-tap investigation of the occurrence of nontuberculous mycobacteria in a full-scale chloraminated drinking water system

APPLIED AND ENVIRONMENTAL MICROBIOLOGY

IF3.7

2024-09-180

OAAI

Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis

CLINICAL MICROBIOLOGY REVIEWS

IF19.3

2024-09-121

PRE

Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis

微生物群落组织指定不同的肺恶化类型并预测囊性纤维化的治疗结果

NATURE COMMUNICATIONS

IF15.7

2024-06-071

OAAI

Novel Ralstonia species from human infections: improved matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification and analysis of antimicrobial resistance patterns

MICROBIOLOGY SPECTRUM

IF3.8

2024-06-045

OAAI

Investigating the suitability of online flow cytometry for monitoring full-scale drinking water ozone system disinfection effectiveness

IF12.4

2024-06-012

PRE

Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations

ANNALS OF THE AMERICAN THORACIC SOCIETY

IF5.4

2024-04-014

PRE

Association of Pseudomonas aeruginosa incident infections with adherence to cystic fibrosis foundation care guidelines

JOURNAL OF CYSTIC FIBROSIS

IF6

2024-03-011

PRE

Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes

JOURNAL OF CYSTIC FIBROSIS

IF6

2024-03-014

PRE

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact

JOURNAL OF CYSTIC FIBROSIS

IF6

2024-01-013

PRE

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2023-11-151

OAAI

Airway bacterial community composition in persons with advanced cystic fibrosis lung disease

晚期囊性纤维化肺病患者的气道细菌群落组成

JOURNAL OF CYSTIC FIBROSIS

IF6

2023-07-014

PRE

Characterizing Biofilm Interactions between Ralstonia insidiosa and Chryseobacterium gleum

MICROBIOLOGY SPECTRUM

IF3.8

2023-04-132

OAAI

Activity of ETX0462 toward Some Burkholderia spp.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2023-01-240

OA

Shower water contributes viable nontuberculous mycobacteria to indoor air

IF3.8

2022-11-1011

OAAI

Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis

开始抗生素治疗囊性纤维化肺恶化后不久，气道细菌群落发生变化

JOURNAL OF CYSTIC FIBROSIS

IF6

2022-09-017

OAAI